Sarah Cannon Research Institute
250 25th Avenue North
Nashville
Tennessee
37232
United States
Tel: 615-342-1919 or 800-242-5662
Website: http://www.sarahcannonresearch.com/
65 articles about Sarah Cannon Research Institute
-
SCRI Announces a Collaboration with AstraZeneca Focused on Technology Enhancements & Innovative Operational Model to Advance Cancer Research
2/28/2024
Sarah Cannon Research Institute announced a collaboration with AstraZeneca, a global, science-led biopharmaceutical company, aimed at advancing innovative technology and operational synergies to enhance the delivery of oncology clinical trials.
-
Sarah Cannon Research Institute to Present Latest Research Insights at the 2023 ASH Annual Meeting & Exposition
12/7/2023
Sarah Cannon Research Institute announced that more than 80 abstracts and presentations have been selected for inclusion at the 65th American Society of Hematology Annual Meeting & Exposition.
-
Sarah Cannon Research Institute to Present Latest Oncology Research Insights at 2023 ASCO® Annual Meeting
6/1/2023
Sarah Cannon Research Institute announced that its network of research leaders have been selected to deliver insights through more than 135 abstracts and presentations at the 2023 American Society of Clinical Oncology Annual Meeting June 2-6, 2023.
-
Vivek Subbiah, MD, Joins SCRI to Advance Early-Phase Clinical Research
5/11/2023
Sarah Cannon Research Institute, one of the world’s leading oncology research organizations conducting clinical trials, is pleased to announce that Vivek Subbiah, MD, has joined the organization as Chief, Early-Phase Drug Development.
-
Harbinger Health and Sarah Cannon Research Institute Launch Clinical Study to Validate and Advance Development of Harbinger’s Novel Early Cancer Detection Platform
6/29/2022
Harbinger Health, a biotechnology company pioneering the detection of early cancer, and Sarah Cannon Research Institute (SCRI) announced today the initiation of a 10,000-participant clinical study designed to validate and further develop Harbinger’s novel platform technology for blood-based early cancer detection.
-
DS-7300 Data at ESMO Shows Promising Early Clinical Activity in Patients with Advanced Solid Cancers
9/17/2021
First-in-human dose escalation results from phase 1/2 study of DS-7300, Daiichi Sankyo’s fourth DXd ADC in clinical development, highlighted in Proffered Paper session at ESMO
-
Sarah Cannon to Present Latest Cancer Research Insights at 2021 ASCO® Annual Meeting
6/4/2021
Today, Sarah Cannon announced it will present its latest cancer research insights at the American Society of Clinical Oncology’s (ASCO®) Annual Meeting being held virtually June 4-8, 2021.
-
Sarah Cannon to Present Latest in Blood Cancer Research at the 62nd ASH Annual Meeting & Exposition
12/4/2020
Sarah Cannon to Present Latest in Blood Cancer Research at the 62 nd ASH Annual Meeting & Exposition
-
Daiichi Sankyo Initiates Clinical Trial with 5th DXd ADC, DS-6157, in Collaboration with Sarah Cannon Research Institute
5/22/2020
Daiichi Sankyo Initiates Clinical Trial with 5 th DXd ADC, DS-6157, in Collaboration with Sarah Cannon Research Institute First-in-human phase 1 trial initiated with DS-6157, a GPR20 directed ADC, in patients with advanced gastrointestinal stromal tumor (GIST) GIST is a rare cancer of the digestive tract with limited treatment options available to patients who progress on standard TKI therapy DS-6157 is the fifth DXd ADC from the oncology pip
-
Daiichi Sankyo Initiates Clinical Trial with its 4th DXd Antibody Drug Conjugate, DS-7300, in Collaboration with Sarah Cannon Research Institute
10/31/2019
First-in-human phase 1/2 study evaluating DS-7300, a B7-H3 targeting ADC, in patients with advanced/unresectable or metastatic solid tumors
-
Daiichi Sankyo and Sarah Cannon Research Institute Launch Strategic Collaboration to Develop Novel Cancer Therapies
12/10/2018
Daiichi Sankyo Company, Limited and Sarah Cannon Research Institute announced today a strategic oncology development collaboration.
-
Sarah Cannon Research Institute – UK Offers TIL Therapy to Patients with Metastatic Melanoma
6/28/2018
Patients in Europe Now Have Access to Cutting-Edge Immunotherapy in Phase II Clinical Trial
-
Sarah Cannon Appoints New Clinical Research and Drug Development Faculty
6/1/2018
Sarah Cannon announced the appointment of three new research faculty to its drug development programs in Nashville, Tenn. and Denver, Colo.
-
Sidney Kimmel Cancer Center – Jefferson Health & Sarah Cannon Research Institute Announce Cancer Drug Development Collaboration
6/1/2018
Collaboration between Sarah Cannon Research Institute and the Sidney Kimmel Cancer Center – Jefferson Health to Enhance Clinical Trial Offerings & Expand Phase 1 Research Capabilities.
-
Sarah Cannon Appoints Axel Grothey as Cancer Research Leader
5/31/2018
Sarah Cannon announced that Axel Grothey, MD, has been appointed the new Director of Gastrointestinal (GI) Cancer Research.
-
Sarah Cannon to Present Latest Cancer Research Insights at 2018 American Society of Clinical Oncology's Annual Meeting
5/31/2018
Sarah Cannon announced that it will present its latest cancer research insights through more than 85 presentations at the American Society of Clinical Oncology’s (ASCO®) Annual Meeting.
-
Sarah Cannon Development Innovations Collaborates with Pivotal on Immuno-Oncology Trials
4/25/2018
arah Cannon Development Innovations announced today a new strategic collaboration with Pivotal to expand access to novel immunotherapies in early phase clinical trials in Europe.
-
START & Sarah Cannon Partner to Advance Therapies for Patients with Cancer
1/17/2018
Partnering on the scientific and operational elements of drug development will lead to even greater efficiencies in the enrollment, quality and excellence of their clinical research programs.
-
Boehringer Ingelheim Expands Collaboration With Sarah Cannon Research Institute to Investigate Novel Immuno-Oncology Combination Therapy
10/30/2017
Boehringer Ingelheim and Sarah Cannon Research Institute today announced an expansion of their strategic partnership which combines Boehringer Ingelheim's oncology research and Sarah Cannon's expertise in clinical trial design.
-
Cancer Experts From Sarah Cannon Research Institute Present Latest In Cancer Research At ASCO's 2017 Annual Meeting
5/25/2017